Company news
Zentalis Pharmaceuticals, Inc. news in 2021
Zentalis Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021
December 1, 2021
Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma
November 16, 2021
Zentalis Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update
November 9, 2021
Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabine in Patients with Osteosarcoma
September 12, 2021
Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3
August 31, 2021
Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
August 11, 2021
Zentera Therapeutics Announces Closing of $75 Million Series B Financing
August 1, 2021
Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma
August 1, 2021
Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 30, 2021
Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, with the First Trial Already Initiated
June 27, 2021
Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock
June 27, 2021
Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock
June 27, 2021
Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
May 16, 2021
Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor
April 11, 2021
Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors
April 9, 2021
Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
March 24, 2021
Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meeting 2021
March 9, 2021
Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors
February 9, 2021
Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials
January 5, 2021
Decks in 2021
- Corporate Update (June 2021)
Corporate update · 44 slides · Jun 28, 2021